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Introduction
Nuclear Protein 1 (NUPR1) is a nuclear intrinsically disordered protein (IDP) of  82 amino acids that plays 
an important role in pancreatic ductal adenocarcinoma (PDAC) (1, 2), as well as other cancers in which 
its genetic inactivation induces tumor growth arrest (3–9). Drug development targeting IDPs is challenging 
due to their dynamic structural features for which a conventional structure-based drug design is not feasi-
ble. We recently developed an efficient multidisciplinary strategy by combining biophysical, biochemical, 
bioinformatics, and biological approaches to perform molecular screening for selecting potential drug can-
didates targeting NUPR1 (10). For fulfilling this aim, we have employed a screening method based on mea-
suring fluorescence thermal denaturation and identified the well-known antipsychotic agent trifluoperazine 
(TFP) as a ligand for NUPR1. Although a strong antitumoral effect of  TFP has been shown in in vitro 
as well as in vivo studies (10), this molecule had a strong narcoleptic side effect at the therapeutic doses. 
Establishing the interactome of the cancer-associated stress protein Nuclear Protein 1 (NUPR1), 
we found that it binds to several hundreds of proteins, including proteins involved in nuclear 
translocation, DNA repair, and key factors of the SUMO pathway. We demonstrated that the NUPR1 
inhibitor ZZW-115, an organic synthetic molecule, competes with importins for the binding to the 
NLS region of NUPR1, thereby inhibiting its nuclear translocation. We hypothesized, and then 
proved, that inhibition of NUPR1 by ZZW-115 sensitizes cancer cells to DNA damage induced by 
several genotoxic agents. Strikingly, we found that treatment with ZZW-115 reduced SUMOylation 
of several proteins involved in DNA damage response (DDR). We further report that the presence 
of recombinant NUPR1 improved the SUMOylation in a cell-free system, indicating that NUPR1 
directly stimulates the SUMOylation machinery. We propose that ZZW-115 sensitizes cancer cells 
to genotoxic agents by inhibiting the nuclear translocation of NUPR1 and thereby decreasing the 
SUMOylation-dependent functions of key proteins involved in the DDR.
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For this reason, a family of  TFP-derived compounds was synthesized based on in silico screening (11). 
Among these molecules, ZZW-115 was the most efficient, as it displayed the best affinity for NUPR1 in 
vitro and showed antitumoral activity 10 times higher than TFP when tested on a large panel of  primary 
PDAC-derived cells and several nonpancreatic cancer cells (12). In addition, ZZW-115 showed a dose-de-
pendent tumor regression in xenografted mice, leading to a nearly total disappearance of  tumors after 30 
days of  treatment in 5 independent PDAC models, including an immunocompetent mice model. In all 
cases, no apparent neurological effect was observed when ZZW-115 was used. Since targeting NUPR1 
by ZZW-115 is highly efficient for treating cancers, it became essential to determine the molecular mech-
anisms by which ZZW-115 exerts its antitumoral activity and eventually to determine other anticancer-as-
sociated functions.
Active transport from the cytoplasm to nucleus occurs via a family of  nuclear transport receptors known 
as importins (or karyopherins), together with other proteins including nucleoporins (NUPs) (13). The clas-
sical importin pathway is initiated by recognition of  proteins having a nuclear localization sequence (NLS) 
by importin-α. The resulting complex is transported through the pore in the nucleus by importin-β and, 
thus, forms a larger complex, which interacts with the FG-rich regions belonging to NUP proteins (14).
Here, we used NUPR1 immunoprecipitation followed by mass spectrometry analysis to generate the 
NUPR1 interactome. We identified 656 NUPR1 interacting partners, among which nuclear proteins were 
highly abundant. We demonstrated that ZZW-115 inhibited the NUPR1 function by hampering its nuclear 
translocation by interfering with its recognition by NUPs. We also found that NUPR1 interacted with 54 
proteins involved in DNA repair machinery, suggesting that NUPR1 could participate in this process, as it 
was previously suggested in studies with male specific lethal protein 1 (MSL1) (15). This led us to hypoth-
esize that administration of  ZZW-115 could improve the effect of  the genotoxic agents by hampering the 
DNA damage response (DDR) and DNA repair processes. This hypothesis was confirmed both in vitro 
and in vivo and was explained by interference with the SUMOylation of  key DDR proteins, including 
several NUPR1 partners, such as TP53, MRE11, and KDM1A. Finally, using a complete cell-free system, 
we demonstrated that NUPR1 improved the SUMOylation of  partner proteins, a function also inhibited by 
ZZW-115, indicating that NUPR1 may affect the SUMOylation — and therefore activation — of  numer-
ous molecules involved in DDR. All these processes are hampered by the presence of  ZZW-115, as NUPR1 
could not be translocated into the nucleus and favor the SUMOylation of  key DDR actors.
Results
Identification of  Flag-NUPR1 partners. To identify the partners of  NUPR1, lysate of  MiaPaCa-2 cells express-
ing a Flag-tagged NUPR1 fusion protein was used. Then, an immunoprecipitation was performed with 
anti-Flag antibodies conjugated beads followed by Flag peptide elution and a liquid-chromatography tan-
dem mass spectrometry (LC-MS/MS) proteomic analysis of  the trypsin digested precipitated proteins. We 
identified 656 proteins capable of  interacting with NUPR1. As expected, since NUPR1 is mainly nuclear, 
the majority of  the partners were nuclear proteins (Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.138117DS1). A bioinformatics analysis using 
the STRING protein-protein interaction database showed a significant enrichment of  proteins involved 
in the following processes: nucleocytoplasmic transport, DNA repair, cellular response to DNA damage 
stimulus, RNA processing, RNA splicing, SUMO E3 ligases with their SUMOylated target proteins, and 
SUMOylation of  proteins devoted to DDR and repair (Table 1). These results indicate that NUPR1 could 
play a significant role in all those cellular processes. In all likelihood, some of  these proteins interact direct-
ly to NUPR1, whereas some other are coprecipitated because they are part of  multiprotein complexes. A 
more detailed study will be further performed to determine the direct partners of  NUPR1.
ZZW-115 inhibits the nuclear transport of  NUPR1 by competing with importins. NUPR1 contains a canon-
ical bipartite domain of  positively charged amino acids, typical of  NLS, localized from residues 63–78 
(16). The interactome of  NUPR1 revealed that this protein was bound to 30 components of  nuclear pore 
including several importins or karyopherins (KPNA1, KPNA2, KPNA3, KPNA4, and KPNA6) and 17 
NUPs. In our previous work, we have shown that NUPR1 binds ZZW-115 via residues around Ala33 
and Thr68 (12). Because Thr68 belongs to the NLS region of  NUPR1, it is reasonable that ZZW-115 
can hinder the interaction between NUPR1 (through its NLS) and importins, and then block the NUPR1 
nuclear translocation. Therefore, by using NUPR1 immunofluorescence staining, we studied the poten-
tial impact of  ZZW-115 on the intracellular location of  NUPR1. We found that treatment with ZZW-115 
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inhibited almost completely the translocation of  NUPR1 from the cytoplasm to the nucleus from 78% 
in control cells to 16% in ZZW-115 treated cells (Figure 1, A and B). We verified this observation in vivo 
by treating nude mice with xenografts, generated by injecting MiaPaCa-2 cells, with ZZW-115 (5 mg/
kg/day for 30 days). The subcellular localization of  NUPR1 was studied by confocal immunofluores-
cence. As expected, NUPR1 showed nuclear localization in untreated xenografts; however, in treated 
animals, the nuclear localization was strongly decreased as presented in Supplemental Figure 1, A and B. 
An interesting point to be noted is that the total fluorescence in treated tumors was strongly decreased. 
Taken together, these results led us to the conclusion that ZZW-115 inactivated NUPR1 by preventing 
its translocation into the nucleus, where it is expected to play its essential roles regarding cell survival, 
especially under stress conditions.
NUPR1 and importin-α3 interact in vitro and in cellulo. Since we had observed an interaction between 
importins and NUPR1 in its interactome, we decided to investigate the interaction between NUPR1 and 
importin-α3 (KPNA4) in vitro by using fluorescence and circular dichroism (CD). We observed changes in 
the fluorescence spectra after excitation at either 280 or 295 nm; since NUPR1 has only 2 tyrosines (Tyr30 
and Tyr36), the changes observed in the fluorescence spectrum by excitation at 295 nm must be due to 
changes in the environment around at least 1 of  the 6 tryptophans in importin-α3 (Figure 2A). Conversely, 
the far-UV CD spectra did not show any change, suggesting that the secondary structure of  importin-α3 
did not change upon binding (Figure 2B). Furthermore, the CD results suggest that NUPR1 remained 
disordered upon binding (as it happens in other complexes formed by the protein) (15, 17). To further 
demonstrate that there was binding between NUPR1 and importin-α3 in vitro, we provide a quantitative 
measurement for this interaction. We carried out isothermal titration calorimetry (ITC) experiments in 
the absence and in the presence of  ZZW-115. The results (Figure 2C and Table 2) indicate that: (a) the 
affinity of  NUPR1 for importin-α3 (association constant of  6.9 × 105 M–1, and dissociation constant of  
1.4 μM) was similar to that shown by NUPR1 toward other biomolecules (15, 17, 18) and for ZZW-115 
(association constant of  4.7 × 105 M–1 and dissociation constant of  2.1 μM; ref. 12); and (b) in the presence 
of  ZZW-115, a 25-fold reduction in the affinity between NUPR1 and importin-α3 was observed (Figure 
2D). The 25-fold reduction caused by ZZW-115 at a concentration of  100 μM obtained with the binary 
system approximation corresponds to a heterotropic cooperativity constant equal to 0.02, which is in good 
agreement considering the experimental error with the value of  0.03 obtained with the analysis performed 
by solving the exact ternary equilibrium. Alternatively, a 21-fold reduction in the affinity for NUPR1 inter-
acting with importin-α3 caused by the presence of  ZZW-115 at 100 μM was calculated from the ternary 
equilibrium analysis, in agreement within the experimental error, with the 25-fold reduction obtained from 
the binary system approximation. If  ZZW-115 was a purely competitive inhibitor, a 45-fold reduction in 
Table 1. Bioinformatics analysis of NUPR1 interactors showed a significant enrichment of nuclear 
proteins
Biological process Count in gene set FDR
Nucleocytoplasmic transport 69/263 P = 7.34 × 10–34
DNA repair 54/491 P = 1.09 × 10–11
Cellular response to DNA damage stimulus 63/749 P = 3.92 × 10–9
RNA processing 183/825 P = 2.30 × 10–84
RNA splicing 130/391 P = 1.35 × 10–75
SUMO E3 ligase SUMOylated proteins 43/154 P = 1.14 × 10–21
SUMOylation of DNA damage response and repair proteins 26/69 P = 6.42 × 10–16
Functional enrichment analysis was performed in STRING v11.0. 
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the affinity for NUPR1 interacting with importin-α3 would be elicited by the presence of  ZZW-115 at 100 
μM, suggesting that mixed inhibition is possible and the formation of  the (nonproductive) ternary complex 
NUPR1/ZZW-115/importin-α3 cannot be ruled out. Then, we confirmed this interaction using the prox-
imity ligation assay (PLA) in MiaPaCa-2 cells transfected with a plasmid expressing the importin-α3–Flag. 
Figure 2E shows that NUPR1 and importin-α3–Flag interact, and this interaction is strongly diminished 
by the treatment with ZZW-115. Therefore, we have quantitatively shown that there was binding in vitro 
and in cellulo between NUPR1 and importin-α3, and the presence of  ZZW-115 hampered that interaction.
Treatment with ZZW-115 sensitizes cancer cells to genotoxic-induced DNA damage. The NUPR1 interactome 
revealed strong and specific abundance of  proteins involved in DNA repair processes (54 NUPR1 interac-
tors out of  491 proteins in this category) and in cellular response to DNA damage stimulus processes (63 
NUPR1 interactors out of  749 proteins in this category) (Table 1). Proteins of  these functional complexes, 
which interact directly with NUPR1, remain to be defined. Hence, we hypothesized that NUPR1 could be 
involved in the DNA repair process and that, by blocking this particular function of  NUPR1, ZZW-115 
could be used to improve the efficacy of  genotoxic agents. We have had preliminary evidence that NUPR1 
could be involved in DNA repair by using several spectroscopic and biophysical techniques because of  its 
interaction with MSL1 (15). Several cancer cell types (PDAC, AOIPC and MiaPaCa-2; glioblastoma, U87 
and U251; colon cancer, HT29) were treated with different genotoxic agents such as 5-fluorouracile (5-FU), 
oxaliplatin, gemcitabine, temozolomide (TMZ), or γ-radiation, alone or in combination with ZZW-115. 
Then, DNA damage was quantified by counting the number of  γH2AX foci (Figure 3 and Supplemental 
Figure 2). As expected, DNA lesions caused by all genotoxic agents were strongly increased when cells 
were cotreated with ZZW-115. Importantly, this potentiation effect was genotoxic agent independent and 
cell type independent (Figure 3 and Supplemental Figure 2). Remarkably, when nontransformed cancer-as-
sociated fibroblasts (CAF) were treated with ZZW-115, no improvement of  DNA damage induced by 5-FU 
was observed (Supplemental Figure 2). As expected, no effect of  ZZW-115 was observed when cells were 
treated with a nongenotoxic agent like sorafenib, a multikinase inhibitor (Supplemental Figure 2). In addi-
tion, to demonstrate that the phenotype observed upon ZZW-115 treatment is due to NUPR1’s inhibition, 
MiaPaCa-2 cells were transfected with siRNAs against NUPR1. Interestingly, NUPR1-depleted cells were 
more sensitive to 5-FU alone than control cells. However, while — in the siRNA control cells — ZZW-
115 induced a synergic effect in combination with 5-FU, in the NUPR1-depleted cells, ZZW-115 did not 
increase the levels of  DNA-damage (Supplemental Figure 2). Thus, we concluded that NUPR1 is involved 
in the DDR and that ZZW-115 targeting of  NUPR1 sensitizes cancer cells to any genotoxic treatment.
Cotreatments with ZZW-115 improve the efficacy of  genotoxic agents on PDAC and glioblastoma in vivo. Because 
the compound ZZW-115 was capable of  improving the DNA damage induced by several genotoxic agents 
Figure 1. ZZW-115 inhibited NUPR1 nuclear translocation. (A) MiaPaCa-2 cells were treated with ZZW-115 (5 μM) for 6 hours. Immunofluorescence with 
rabbit anti-NUPR1 primary antibody and Alexa 488–labeled goat anti-rabbit secondary antibody were used to reveal the localization of the protein. DAPI 
staining was used to detect cell nuclei, and it was combined with the Alexa 488 fluorescence in the merged panel. Scale bars: 10 µm. representative experi-
ment is shown (n = 3). (B) Intensity profiles along the white line in the image are shown. Colocalization scatter plot, Pearson’s R value (PRV), and Mander’s 
coefficient (MC) were calculated by using the ImageJ Coloc2 plugin; a representative experiment is shown (n = 3).
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on different cell types in vitro, we wondered whether this could also happen in vivo. To this purpose, we 
chose to follow the development of  MiaPaCa-2 PDAC and U87 glioblastoma cells xenografted in mice 
treated with 5-FU and/or ZZW-115 or TMZ and/or ZZW-115, respectively.
PDAC. MiaPaCa-2 xenograft grew in an exponential manner when treated with vehicle solution (from 
326.64 ± 15.00 mm3 to 1813.60 ± 92.93 mm3 during 30 days). When mice were treated with 5-FU or ZZW-
115 alone, the tumors grow from 298.81 ± 34.98 mm3 to 1019.19 ± 113.01 mm3 and from 345.43 ± 67.77 
mm3 to 746.71 ± 67.64 mm3, respectively. Remarkably, the size of  the tumors of  all mice treated with the 
combination of  5-FU and ZZW-115 decreased immediately after the injections of  the drug combination, 
Figure 2. NUPR1 interacted with importin-α3 in vitro. (A) Fluorescence spectrum of the complex formed by importin-α3 and NUPR1 (red) and that 
obtained by the addition of the spectra of both isolated biomolecules after excitation at 280 nm (blue). (B) Far-UV CD spectrum of the complex formed by 
importin-α3 and NUPR1 (red) and that obtained by the addition of the spectra of both isolated biomolecules (blue). (C and D) ITC raw data (top, thermal 
power [dQ/dt], as a function of time [t]) and titration curve or binding isotherm (bottom, ligand-normalized injection heats [Q], as a function of the reac-
tants molar ratio) for the interaction between importin-α3 and NUPR1 in the absence (C) or presence (D) of ZZW-115. (E) PLA was performed in MiaPaCa-2 
cells transfected with a plasmid expressing importin-α3–Flag in the presence or absence of ZZW-115 (5 μM) for 6 hours. Mouse anti-Flag and rabbit anti-
NUPR1 antibodies were used. A representative experiment is shown (n = 3). ImageJ was used to count the number of red dots. Data represent mean ± SEM 
of 6 field, Student’s 2-tailed unpaired t test was used, **P < 0.01.
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until their disappearance (from 368.24 ± 45.00 mm3 to 28.48 ± 8.59 mm3) (Figure 4, A and B). To reveal 
the molecular mechanisms by which ZZW-115 exerts its effect on MiaPaCa-2, we performed immunofluo-
rescence staining for γH2AX, cleaved caspase-3, and Ki67 to measure DNA damage, apoptosis, or antipro-
liferative effects. As shown in Figure 4C, tumors treated with the 5-FU/ZZW-115 combination displayed a 
large proportion of  cells with DNA damage, greater number of  apoptotic cells, and less proliferating cells 
— compared with single or no treatments.
Glioblastoma. When U87 tumors reached a volume of  about 300 mm3, we started a daily treatment with 
5 mg/kg of  TMZ or ZZW-115 (2.5 mg/kg) either alone or in combination. The control group received the 
same volume of  vehicle solution. Tumor volumes increased in an exponential manner in control mice (from 
315.60 ± 6.25 mm3 to 1471.00 ± 176.80 mm3 during 21 days). When mice were treated with TMZ, the 
tumors had a slower development (from 334.30 ± 9.80 mm3 to 950.50 ± 290.85 mm3) (Supplemental Figure 
3, A–C); tumors from mice treated with ZZW-115 also grew more slowly than in control mice (from 336.00 
± 28.10 mm3 to 903.50 ± 280.90 mm3). A significant intragroup variation was observed in both TMZ and 
ZZW-115 single-treated mice (Supplemental Figure 3, A–C). However, the size of  the tumors of  all mice 
treated with the combination of  TMZ and ZZW-115 decreased immediately after starting the injections of  
the compounds and almost disappeared after 21 days of  treatment (from 329.00 ± 27.00 mm3 to 24.30 ± 5.10 
mm3). Results obtained for this group were much more homogenous since all tumors displayed a continuous 
regression until their complete disappearance (Supplemental Figure 3, A–C). Interestingly, we observed no 
tumor relapse in this group with combinatorial treatment, even after 25 days with no further treatment (data 
not shown). In addition, γH2AX, cleaved caspase-3, and Ki67 were stained to measure DNA damage, apop-
tosis, and antiproliferative effects, respectively. The tumors treated with the TMZ/ZZW-115 combination 
had a greater proportion of  cells with DNA damage, large number of  apoptotic cells, and less proliferating 
cells — compared with single treatments or control condition (Supplemental Figure 3D).
NUPR1 localizes at DNA damaged sites and interacts with DNA repair proteins after treatment with DNA damaging 
agents. Since pharmacological inhibition of NUPR1 exacerbates DNA damage, we were interested to probe 
if  NUPR1 interacts with the DNA-repair proteins, which are recruited in these areas and were identified in 
the NUPR1’s interactome. In order to demonstrate that NUPR1 interacts with DNA repair proteins, we per-
formed PLAs between NUPR1 and MRE11 or TP53. In both cases, positives PLA signals were observed in 
control conditions. However, as expected, incubation with ZZW-115 was capable of hampering this interaction 
(Figure 5A). Moreover, since NUPR1 interacts with DNA repair proteins, we demonstrated that NUPR1 is 
localized at the DNA lesions by performing a PLA between NUPR1 and the γH2AX (Figure 5B). Importantly, 
5-FU treatment induced a greater interaction between both proteins, while this effect was almost completely 
reversed in the presence of ZZW-115. Taken together, these experiments demonstrate that NUPR1 interacts 
with DNA repair proteins and that it is localized at the DNA lesions.
Analysis of  protein PTMs intervening after treatments with 5-FU alone or in combination with ZZW-115. Our 
previous results support the idea that NUPR1 was involved in DNA-repair processes induced by geno-
toxic agents. These DDR pathways rely on several posttranslational modifications (PTMs) of  essential 
proteins to be activated and fully functional. Besides phosphorylation, PTMs mediated by ubiquitin and 
Ub-like members, such as SUMOs and Nedd8, were also shown to play crucial role in this process (19, 
20). Therefore, we were interested in identifying changes within PTM profiles of  main ubiquitin family 
members induced by a DNA damaging agent, 5-FU, alone or in combination with ZZW-115 in MiaPaCa-2 
cells. Ubiquitinated, SUMOylated and Neddylated proteins were isolated from treated (see Methods) and 
untreated cells, and modified proteins were identified and semiquantified by MS.
Table 2. Thermodynamic parameters for the Importin-α3/NUPR1 interaction determined by ITC 
experiments (experiments were carried out at 25°C)
Importin-α / NUPR1 Ka (M–1) Kd (μM) ΔH (kcal/mol)
–ZZW-115 6.9 × 105 1.4 –13.7
+ZZW-115 2.8 × 104 35 –61
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A total of  1762 SUMOylated proteins were identified: 1404 in untreated cells, 450 alterations 
induced by 5-FU treatment (319 upward variations [up] and 131 downward variations [down]), 345 
alterations induced by ZZW-115 treatment (136 up and 209 down), and 385 alterations induced by 
the cotreatment with both compounds (148 up and 237 down) (Table 3 and Supplemental Table 2). 
Interestingly, most 5-FU–induced SUMOylations were found to be inhibited when cotreated with 
ZZW-155 (Supplemental Table 3). Indeed, among the 319 proteins SUMOylated in response to the 
5-FU treatment, only 2 seemed to be insensitive to the inhibitory effect of  ZZW-155. A total of  1922 
ubiquitinated proteins were identified, from which 1492 were found in untreated cells (Table 3 and 
Supplemental Table 4). Contrary to SUMOylations, 5-FU treatment induced a global decrease of  
ubiquitination rather than an increase, 345 and 133 proteins, with decreased and increased ubiquitina-
tions, respectively). ZZW-115 induced mainly decreased ubiquitination (732 proteins) while only 58 
proteins exhibited increased ubiquitination. Finally, the cotreatment with both drugs resulted in 460 
Figure 3. NUPR1 inhibition by ZZW-115 potentiated the efficacy of genotoxic agents in primary PDAC cells. The efficacy of different genotoxic agents 
(5-FU, Oxaliplatin, γ-radiation, and gemcitabine) to generate DNA breaks in AOIPC primary PDAC cells and the boosting effect of ZZW-115 was evaluated 
by γH2AX immunofluorescence staining. Quantifications of 3 independent experiments were used to evaluate the statistical significance, and they are 
shown as graphics. ***P < 0.001; ****P < 0.0001 (1-way ANOVA, Tukey’s post hoc test). Data represent mean ± SEM, n = 3.
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and 150 proteins, with increased and decreased ubiquitinations, respectively (Table 3). The establish-
ment of  Nedd8-specific proteome led to the identification of  1696 Neddylated proteins, 1203 of  which 
were found in untreated cells. Treatments with 5-FU, ZZW-115, or both molecules resulted mostly in 
increased Neddylations (285, 291, and 476 proteins, respectively) and a minority of  deneddylations 
(114, 99 and 84 proteins, respectively) (Table 3 and Supplemental Table 5).
These inductions/repressions of  PTMs induced by the different treatments were so important for some 
proteins that they could be observed only in the treated or nontreated groups (Supplemental Figure 4). We 
used the Panther GeneOntology online tool (http://www.pantherdb.org/) to study the biological processes 
mostly affected by the treatment with 5-FU (Supplemental Table 6). 5-FU induced alterations of  SUMOyla-
tion; ubiquitination and Neddylations were involved in hundreds of  different biological processes. However, 
when searching specifically for DNA-associated biological functions, we noticed that altered SUMOylations 
were involved in 6 of  them, whereas altered ubiquitinations and Neddylations were involved in only 3. Most 
importantly, only alterations of  SUMOylations displayed a specific enrichment in the DNA repair process. 
Figure 4. ZZW-115 strongly potentiated the antitumoral activity of on PDAC genotoxic agents in vivo. CAnN.Cg-Foxn1nu/Crl BALB/c nude mice xeno-
grafted with MiaPaCa-2 cells were separated into 4 groups of 5 mice and treated daily for 30 days with 0.5% DMSO in physiologic serum (control group), 
20 mg/kg 5-FU, 2.5 mg/kg ZZW-115, or 20 mg/kg 5-FU in combination with 2.5 mg/kg ZZW-115. Tumor volume was measured every 3 days. (A and B) Indi-
vidual volume of each mouse (A) and mean of the volume of each treatment (B) are shown. For each treatment, statistical significance is **P < 0.01 and 
***P < 0.001 (1-way ANOVA, Tukey’s post hoc test). (C) Immunostaining of tumor samples with antibodies against Ki67, cleaved caspase-3, and γH2AX. 
Quantification of foci was performed by ImageJ software on 3 samples of each group. For each treatment, statistical significance is ***P < 0.001, ****P < 
0.0001 (1-way ANOVA, Tukey’s post hoc test). Data represent mean ± SEM, n = 3.
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This enrichment contained 23 proteins with altered SUMOylations provoked by 5-FU, 14 of  which with 
increased and 9 with decreased SUMOylations (Table 4). Noticeably, all of  these 5-FU–induced SUMOy-
lations were inhibited by ZZW-115 cotreatment (Table 4 and Supplemental Figure 5). Collectively, the pro-
teomic data show that 5-FU treatment induced the hyper-SUMOylation of  a number of  proteins involved 
in the DDR, a process that was suppressed when the 5-FU treatment was combined with ZZW-115. We 
next aimed at validating these alterations of  SUMOylations by specifically studying the behavior of  some 
proteins among the identified targets. Using standard purification of  SUMOylated proteins followed by 
Western blots, we could confirm as a proof  of  concept that the central DNA repair protein MRE11, TP53, 
and the histone demethylase KDM1A were all hyper-SUMOylated in response to 5-FU treatment and, 
importantly, that this response was efficiently inhibited by the cotreatment with ZZW-155 (Figure 5C).
Figure 5. NUPR1 interacts with DNA repair proteins at DNA lesions, and its inhibition induces alterations of protein posttranslational modifications 
(PTM) profiles. (A) PLA was performed in MiaPaCa-2 cells, treated or not with ZZW-115 (5 μM) for 6 hours, transfected with a plasmid expressing NUPR1-
Flag, using rabbit antibodies against MRE11 or TP53 and mouse anti-Flag. A representative experiment is shown (n = 3). ImageJ was used to count the 
number of red dots. Data represent mean ± SEM of 6 fields. Student’s 2-tailed unpaired t test was used. **P < 0.01; ***P < 0.001. (B) PLA was performed 
in MiaPaCa-2 cells (treated or no with ZZW-115 at 1.5 μM, 5-FU at 10 μM, or the combination of both for 24 hours) using rabbit anti-NUPR1 and mouse 
anti-γH2AX antibodies. Nontreated or treated with ZZW-11A representative experiment is shown (n = 3). ImageJ was used to count the number of red dots. 
Data represent mean ± SEM of 6 fields. One-way ANOVA with Tukey’s post hoc test was used. **P < 0.01. (C) Variations of SUMOylation of 3 identified 
DNA repair proteins and variations following the different treatments were studied by Western blot after purification of SUMOylated proteins in denatur-
ing condition by Ni2+ pull-down. The upper parts of nitrocellulose filters were immunoblotted using anti-MRE11–, -TP53–, and -KDM1A–specific antibodies. 
Lower parts of filters were blotted using anti-Flag antibody in order to control the equal amount of precipitated material. Signals were quantified by 
densitometry, and values of the ratio of SUMOylated bands over precipitated SUMO1 are shown. Asterisk represents nonspecific bands (n = 1). (D) PLA was 
performed on MiaPaCa-2–6HF–SUMO1 cells transfected with siRNA against NUPR1 and treated with 5-FU and/or ZZW-115 (same conditions as mentioned 
above). SUMOylation of TP53 was quantified by mouse anti-Flag and rabbit anti-TP53 antibodies. A representative experiment is shown (n = 3). ImageJ 
was used to count the number of red dots. Data represent mean ± SEM of 6 fields. One-way ANOVA with Tukey’s post hoc test was used. ***P < 0.001.
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Then, we studied whether inactivation of  NUPR1 by a siRNA interference approach shows similar 
consequences as ZZW-115 treatment on the TP53 SUMOylation. To do this, we treated the MiaPaCa-2, 
stably transfected with SUMO1 (21), with siRNA against NUPR1 and then treated them with 5-FU. 
SUMOylation of  TP53 was quantified by PLA using mouse anti-Flag and rabbit anti-TP53. As expected, 
SUMOylation was strongly improved after the treatment with 5-FU, but this increase was almost complete-
ly inhibited by ZZW-115. Treatment with siNUPR1 showed a dramatic inhibition of  the SUMOylation 
as presented in Figure 5D. Altogether, our findings demonstrate that NUPR1 specifically takes part in the 
DNA repair process as it is involved in the mechanisms responsible for the increased SUMOylations, such 
as TP53, induced by a genotoxic agent like 5-FU.
NUPR1 improved SUMOylation in a cell-free system. The interactome of  NUPR1 revealed that it interacts 
directly or indirectly with UBC9 (the main SUMO conjugating enzyme), SUMO1, SUMO2/3, and RANBP2 
(a major SUMO E3 ligase). Therefore, we hypothesized that NUPR1 could improve the SUMOylation of  
many proteins by acting as a stabilizer of  the SUMOylation complex, mainly UBC9-SUMO and RANBP2. 
To test this possibility, we performed in vitro SUMOylation assays for SUMO1 and SUMO2/3, using recom-
binant RanGAP1 and p53 as substrates in the presence of: (a) recombinant WT NUPR1 (rNUPR1); (b) 
the recombinant Thr68Gln or Ala33Gln/Thr68Gln NUPR1 mutants; or (c) rNUPR1 in the presence of  
ZZW-115. Those 2 rNUPR1 mutants, with mutated residues belonging to either of  the 2 hot-spot regions of  
NUPR1, have been designed to hamper interactions of  NUPR1 with its natural partners (proteins or DNA) 
(17). The presence of  WT rNUPR1 significantly increased the SUMOylation of  the RanGAP1 and p53 
substrates with both SUMO1 (Figure 6, A and C) and SUMO2/3 (Figure 6, B and D). Conversely, neither 
the presence of  the mutants or, alternatively, NUPR1 together with ZZW-115 did increase the SUMOylation. 
Therefore, by interacting both with the SUMOylation machinery and with SUMOylation substrates, NUPR1 
had the ability to stabilize the whole complex, thereby improving the SUMOylation of  many proteins — 
some of  which belong to the DDR.
Discussion
Here, we describe the mechanism by which the previously designed bioactive compound ZZW-115 inhibits 
the nuclear activity of  NUPR1. In particular we found that ZZW-115 interacts with NUPR1 through resi-
due Thr68, which belongs to its predicted NLS sequence. The binding of  the compound hampers the acces-
sibility of  the NLS to importin and then hinders the binding between the 2 biomolecules. We also found in 
vitro and in vivo that treatment of  cells from several cancer types with ZZW-115 improved the anticancer 
activity of  some, if  not all, genotoxic agents, including radiations, by interfering with the SUMOylation of  
key proteins involved in the DDR.
ZZW-115 shifted importins of  the importin-cargo complex. NUPR1 is a small IDP protein with a typical NLS 
sequence at its C-terminal region. Due to its disordered nature (and thus a large hydrodynamic radius), it 
Table 3. Alterations of protein translational modifications (PTM) profiles upon treatment with 5-FU in isolation or in combination with 
ZZW-115.
Ctrl 5-FU ZZW-115 5-FU + 
ZZW-115
Total PTMs
SUMO 1404 ↑ 319 ↑ 136 ↑ 148 1762
↓ 131 ↓ 209 ↓ 237
↕ 450 ↕ 345 ↕ 385
Ubiquitin 1492 ↑ 133 ↑ 58 ↑ 460 1922
↓ 345 ↓ 732 ↓ 153
↕ 478 ↕ 790 ↕ 613
Nedd8 1203 ↑ 285 ↑ 291 ↑ 476 1696
↓ 114 ↓ 99 ↓ 84
↕ 399 ↕  390 ↕ 560
Table showing for each PTM the number of identified proteins in total, in control condition, and the number of variations induced by 5-FU and ZZW-115 
treatments, alone or in combination (upward arrows indicate increased PTMs, downward arrows indicate decreased PTMs, and arrows pointing upward and 
downward indicate total variations of PTMs).
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needs to be transported from the cytoplasm to the nucleus to play its critical role for cancer cells. By using 
a proteomic-based strategy, we found that NUPR1 binds to proteins belonging to the nuclear pore complex 
(NPC). Our current knowledge of  nuclear translocation indicates that the initial step of  the classical nuclear 
transport process is the formation of  the importin-cargo complex, in which importins bind cargo molecules 
after recognition of  their NLS. Then, the N-terminus of  importin-α (importin-β binding domain) binds to 
importin-β (22, 23). After the formation of  the importin-cargo complex, importin-β is specifically recruited 
to NPC in the nuclear pore, and then the complex can pass through the nuclear pore. Each importin isoform 
has its own specific cargo molecules. We explored in vitro the binding between the importin-α3 isoform and 
NUPR1. The binding affected some of  the aromatic residues of  importin (as indicated by the changes in flu-
orescence), but it did not cause any change in the secondary structure of  both proteins (as pinpointed by the 
absence of  changes in CD spectra); NUPR1 remained disordered upon binding, forming a fuzzy complex 
(as it happens in the presence of  other partner biomolecules) (15, 17, 18). The affinity of  importin-α3 for 
NUPR1 was slightly greater (dissociation constant of  1.4 μM) than that of  NUPR1 for ZZW-115 (4.7 × 105 
M) (12), although the enthalpy change associated with the former binding reaction was much larger (–13.7 
kcal/mol versus –0.4 kcal/mol), likely reflecting more interactions established by NUPR1 with impor-
tin-α3, a 58 kDa protein, than with ZZW-115, a small molecule. As expected, the affinity of  importin-α3 for 
NUPR1 was dramatically decreased in the presence of  ZZW-115 (dissociation constant of  35 μM at 100 μM 
ZZW-115, Table 2). We then demonstrated, by using an independent and complementary approach named 
PLA, that NUPR1 interacted with importin-α3 in cellulo, in agreement with proteomic and biophysical 
analyses. Although importin-α3 and ZZW-115 have a similar affinity for NUPR1, ZZW-115 can shift the 
binding equilibrium between the 2 biomolecules (a) because of  its smaller size (ZZW-115 binding to NUPR1 
would be kinetically favored against that of  NUPR1 to importin-α3); (b) if  present at a comparable or higher 
concentration than that of  importin-α3; and (c) if  the potential ternary complex NUPR1/ZZW-115/impor-
tin-α3 is deficient regarding nuclear translocation. Altogether, these data show that ZZW-115 binds to the 
NLS region of  the NUPR1 by partially shifting the binding equilibrium of  NUPR1 with the importin and 
therefore acting as an inhibitor of  its nuclear translocation.
Table 4. Log2 induction SUMOylation ratio
DDR genes 5-FU ZZW-115 5-FU + ZZW-115 Percent inhibition of 5-FU  by ZZW-115
BABAM2 19.41 0.00 0.00 –100.00
CLU4A –5.76 –26.03 –26.03 351.91
CLU4B –5.54 –26.15 –26.15 372.01
EGFR 20.25 0.00 0.00 –100.00
EMSY 18.90 0.00 0.00 –100.00
ERCC3 20.39 0.00 19.73 –3.22
GPS1 –19.08 –19.08 –19.08 0.00
HSF1 21.23 20.80 0.00 –100.00
INO80B 19.61 0.00 0.00 –100.00
KDM1A 19.60 0.00 0.00 –100.00
MARF1 –17.34 –17.34 –17.34 0.00
MRE11 2.43 0.85 0.26 –89.18
POLD1 17.91 0.00 0.00 –100.00
RBM14 19.65 0.00 18.37 –6.52
RFC3 –17.56 –17.56 –17.56 0.00
TDG –19.46 –0.04 –19.46 0.00
TFPT 21.57 21.51 20.62 –4.40
TP53 22.33 21.12 21.32 –4.52
TRIP12 –18.04 –0.42 –18,04 0.00
UNG 21.23 0.00 0.00 –100.00
WRNIP1 –20.28 –20.28 –0.80 –96.04
ZBTB1 19.01 0.00 0.00 –100.00
For each protein involved in DNA repair and undergoing alteration of SUMOylation after 5-FU treatment, the ratio of induction or repression of 
SUMOylation induced by each treatment is shown, and the percentage of inhibition of 5-FU induced alterations of SUMOylations by ZZW-115 treatment.
 
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.138117
R E S E A R C H  A R T I C L E
Until recently, the palette of  nuclear transport inhibitors had been limited to the inhibition of  XPO1 by 
Leptomycin B (LMB) — which, however, failed during phase I clinical trials due to its toxicity (24). Since 
the discovery of  LMB, an increasing number of  new inhibitors of  nuclear transport mediated by importins 
have been reported, but all retain their persistent toxicity due to their lack of  specificity. On the contrary, a 
limited number of  inhibitors that target specific cargos have been reported (25, 26). The first cargo-specific 
nuclear transport inhibitor described was mifepristone, a specific inhibitor of  recognition of  HIV-1 inte-
grase by importin-α/β (27). There has been limited progress in the last few years in identifying and char-
acterizing nuclear transport inhibitors due to their high toxicity. Since ZZW-115 specifically binds NUPR1 
at residues involved in its NLS region, it shifts importins in a cargo-specific manner. We also assume that 
its toxicity, if  any, will be low because there is no binding to the importin. In fact, thermal denaturations 
followed by CD indicate that the binding of  ZZW-115 to importin-α3 does not take place (data not shown). 
Screening and identification of  high-affinity compounds, using the NLS-specific cargos used as bait, could 
be a worthy strategy to identify new targets of  nuclear proteins, as it has been suggested (25, 26, 28).
NUPR1 promotes SUMOylation in response to genotoxic stress. In response to DNA damage, induced by 
both genotoxic agents and radiation, cells activate a highly conserved and complex kinase-based signaling 
network, commonly referred to as the DDR, to safeguard genomic integrity. The DDR consists of  a set 
of  tightly regulated events, including detection of  DNA damage and accumulation of  DNA repair factors 
at the site of  damage. The DDR imposes a cell cycle arrest to allow the DNA repair to take place and to 
preserve genome stability (29). Several PTMs occur during DDR (30), and among them, ubiquitinylation 
and SUMOylation have focused wide attention. Both Ubiquitylation and SUMOylation coordinate various 
pathways involved in DNA damage recognition and signaling and promote DNA repair (31). DNA repair 
factors have been identified to be SUMOylated and found to be enriched in the nuclear compartment after 
DNA damage (32, 33). SUMOylation regulates nuclear structures and is critical for multiple functions, 
including chromosome movement, centromeric functions, and DDR (34). Importantly, SUMO is thought 
to act synergistically on multiple proteins to create an environment favoring efficient DNA repair, probably 
by physically stabilizing the interactions between the proteins of  the DNA repair machinery complexes (35). 
Figure 6. NUPR1 improved SUMOylation levels in vitro. (A and B) Western blot of in vitro SUMOylation by SUMO1 (A) or SUMO2/3 (B) of RanGAP1 was 
performed with no treatment or in the presence of recombinant WT rNUPR1, Thr68Gln, and Ala33Gln/Thr68Gln rNUPR1 mutants, as well as WT rNUPR1 in 
presence of ZZW-115. (C and D) Western blot analysis of in vitro SUMOylation by SUMO1 (C) or SUMO2/3 (D) of p53 was performed with no treatment or in 
the presence of recombinant NUPR1. **P < 0.01 compared with no treatment (1-way ANOVA, Tukey’s post hoc test). Data represent mean ± SEM, n = 4.
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Recently, interplay between SUMOylation and phosphorylation in response to replication stress were 
shown to protect DNA integrity (36).
In this work, we show that 450 proteins were differentially SUMOylated in 5-FU–treated cells, and 
SUMOylation of  many of  them was reversed by the addition of  ZZW-115, indicating that NUPR1 plays 
a major role in controlling SUMOylation after 5-FU treatment. Importantly, a substantial amount of  these 
proteins is involved in the DDR, and many of  them are known to be regulated by SUMOylation (Table 
4). This general effect of  NUPR1 was confirmed on 3 targets involved in the DDR (MRE11, TP53, and 
KDM1A), for which hyper-SUMOylated in response to 5-FU treatment was inhibited by the cotreatment 
with ZZW-155 (Figure 5C). Although MRE11, TP53, and KDM1A play important roles in the DDR, the 
role of  their SUMOylation in response to DNA damage has not yet been reported. TP53 has been shown to 
be SUMOylated (37, 38), although the consequences of  its SUMOylation remains unclear (39). KMT1 and 
yeast Mre11 have been both shown noncovalently linked with SUMO1 (40, 41). Our results suggest that 
they are linked covalently to SUMO after genotoxic treatment. Notably, we confirmed that SUMOylation 
of  proteins involved in DDR depends on NUPR1 activity, since its knocking down with specific siRNA 
decreased the SUMOylation of  the TP53 after DDR induced with 5-FU (Figure 5D).
SUMOylation assay performed in a cell-free system showed that rNUPR1, but not Thr68Gln and 
Ala33Gln/Thr68Gln mutants (involving residues belonging to the hot-spot regions of  NUPR1), enhanced 
the SUMOylation of  recombinant RanGAP1 and p53 (Figure 6). The absence of  enhancement in the 
SUMOylation by the mutants is probably due to the fact that complex formation involves the same 2 
regions of  NUPR1 (residues around Ala33 and Thr68), which also intervene in binding with other proteins. 
Importantly, adding ZZW-115 during the complex formation inhibited the effect of  rNUPR1, by binding to 
Thr68 and Ala33 (causing the same effect as the 2 mutations). Altogether, we can assume, although it was 
not formally demonstrated, that NUPR1 acted as a general facilitator of  the SUMOylation by binding and 
stabilizing the complex formed between the SUMOylation machinery and the substrate proteins (i.e., to 
the complex formed by several proteins), as suggested by the NUPR1 interactome (Table 1). Interestingly, 
5-FU cotreatment with ZZW-115 induced mainly an increase in ubiquitinylations and many decreased 
SUMOylations (Table 3), suggesting a stimulation of  the ubiquitin-dependent protein degradation.
ZZW-115 sensitizes cancer cells to DNA damage–based radio and chemo therapies. The success of  the use 
of  physical and chemical DNA damaging agents as anticancer therapeutics is based, and mainly relies, 
on the uncontrolled proliferation of  cancer cells. Indeed, many genotoxic agents target the replication 
stage of  the cell cycle, when cells need to duplicate their genome, to control and guarantee the quality 
of  the produced new DNA. Therefore, the efficacy of  such treatments is further enhanced in cancer cells 
containing a defect in DDR. However, many tumors are, or become, resistant to these kinds of  therapies. 
These resistance mechanisms include, among others, reduced uptake of  the drug by the tumor cells, an 
increased intracellular or systemic inactivation of  the drug, a general resistance to stress-induced cell 
death, and the increased efficiency of  DNA repair mechanisms. Therefore, some strategies have the aim 
to lower the resistance of  cancer cells to genotoxic agents. Most of  these potentiating molecules, but not 
all, do not target directly the DNA damage repair mechanisms but target pathways involved in cell sur-
vival/death or aim at increasing the uptake, activation, and stability of  the genotoxic drugs. Hence, these 
molecules are having a more additive effect than a potentiating outcome on the genotoxic agent. Here, we 
propose that specific inhibition of  NUPR1 function by ZZW-115 displayed a strong potentiating effect of  
several genotoxic agents and on diverse cancer cell types by directly impairing the SUMOylation (Figure 
5) of  the proper function of  the major DNA repair actors (Figure 3) or their molecular partners. We do not 
formally rule out that ZZW-115 could exert its anticancer activity by preventing the binding of  NUPR1 
to factors involved in RNA splicing and processing; however, the fact that ZZW-115 has a synergic effect 
mainly with genotoxic agents and that it inhibits 5-FU–induced SUMOylation rather support our model. 
We therefore presume that ZZW-115 decreases the SUMOylation by targeting NUPR1, which in turn 
decreases DNA repair and consequently increases cell death. In this work, we do not demonstrate that 
a direct effect of  inhibition of  NUPR1-dependent SUMOylation by ZZW-115 is beneficial to anticancer 
activity — rather, we demonstrate its effect on SUMOylation. However, in the literature, the work of  
Biederstadt and colleagues (42) shows that inhibition of  SUMOylation by small compounds has a strong 
effect on aggressive PDAC, indicating that SUMOylation is an essential process for PDAC development 
and survival. Taken together, we suggest that ZZW-115 treatment, as well as inhibition of  NUPR1 by 
siRNA, promotes cell death in response to DNA damage by inhibiting SUMOylation.
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Other molecules addressing — more specifically — the DDR, such as PARP inhibitors, cell cycle 
checkpoint inhibitors, or proteins involved in base excision repair or in double-strand break (DSB) repair, 
have been shown to sensitize cancer cells to radiotherapy (43). However, because DNA repair mechanisms 
are also effective in noncancerous cells and are necessary to warranty their genome stability, they might 
have serious side effects for the patients. Hence, one advantage of  a compound like ZZW-115 is that it 
potentiates the effect of  genotoxic agents by targeting a stress-induced protein, NUPR1, which is abnormal-
ly present in many cancer cells but almost absent from normal cells. In this way, we confirmed that ZZW-
115 was unable to modify the effect on DNA damage induced by the genotoxic agent 5-FU in human non-
transformed fibroblasts (Supplemental Figure 2). Future use in other animal models, and hopefully clinical 
trials, should confirm the low systemic toxicity of  NUPR1 inhibition as we observed in xenografted mice 
cotreated with TMZ or 5-FU and ZZW-115. Indeed, no general toxicity was observed in the mice, whereas 
their xenografted tumors completely disappeared (Figure 4 and Supplemental Figure 3).
Conclusion. To sum up, ZZW-115 interacts with the NLS sequence of  NUPR1 with similar affinity as 
that of  importins for the protein and is able to interfere with the binding reaction between importin-α3 and 
NUPR1, hampering the nuclear translocation of  the latter. Treatment with ZZW-115 enhanced the DNA 
damage induced by genotoxic agents, both in vivo and in vitro, through significantly altering the PTM pro-
files, mainly SUMOylation, and therefore affecting the DDR. ZZW-115 is a promising candidate to be used 
in combination with genotoxic agents potentially in the treatment of  most cancers.
Methods
Flag-NUPR1 coimmunoprecipitation. MiaPaCa-2 cells, expressing Flag-NUPR1 or Flag-GFP, were plated 
in 10 cm2 dishes. When MiaPaCa-2 cells expressing Flag-NUPR1 or Flag-GFP reached 70% confluence, 
they were lysed on ice by using HEPES-based lysis buffer containing 10 mM NEM (N-Ethylmaleimide, 
MilliporeSigma, 04259) and a proteases inhibitor cocktail (1:200) (MilliporeSigma, P8340). Lysates were 
centrifuged for 10 minutes at 21,000g at 4°C. Protein concentration of  the supernatant was determined 
by using Protein Assay (Bio-Rad), and equal amounts of  total protein were used to incubate with 30 μL 
of  anti–Flag M2–coated beads (MilliporeSigma, F3165) under rotation for 2 hours at 4°C. Beads were 
then washed 3 times with cold lysis buffer, and proteins were eluted using 250 μL ammonium hydrogen 
carbonate buffer containing 0.1 μg/μL of  Flag peptide (MilliporeSigma, F3290) for 90 minutes at 4°C 
while rotating. After a short spin, the supernatant was recovered by using a Hamilton syringe. Eluted 
proteins were collected and analyzed by MS.
Lentiviral infection of  MiaPaCa-2 cells with 6His-Flag-ubiquitin–like constructs. A tandem 6His and Flag tag 
was introduced into empty pCCL-WPS-mPGK lentiviral vector, at the 5′ end of  the multicloning sites por-
tion, to produce the pCCL-6HF vector. The full-length cDNA for human ubiquitin, Nedd8, and SUMO1 
were subcloned into this vector using SmaI and EcoRV restriction sites for ubiquitin, BamHI, and EcoRV for 
Nedd8, and BamHI for SUMO1. Lentiviral particles were generated by transfecting 293T cells with a mix of  
1/3 pCCL construct (Ub, Nedd8, SUMO1, or GFP), 1/3 delta Helper and 1/3 pVsVg, using Lipofectamine 
reagent (Invitrogen) and following manufacturer’s recommendations. Beyond 24 hours after transfection, 
the medium was changed with a fresh one. After another 24 hours, medium was changed again and virus-
es contained in the medium were collected, filtered through a 0.2 μm filter, and added on 40% confluent 
MiaPaCa-2 cells seeded in 25 cm2 flasks. This step was repeated 24 hours later to perform a second infection.
Two-step purification of  6His-Flag-ubiquitin, -Nedd8, and -SUMO1 conjugates. MiaPaCa-2 cells expressing the 
6His-Flag-ubiquitin–like constructs or GFP were seeded in 150 mm dishes, at 1 × 106 cells per dish, and when 
they reached 70% confluence, they were treated with 5-FU or ZZW-115 or the combination of both drugs for 
12 hours. Then, approximately 100 (MiaPaCa-2–6His–Flag–ubiquitin and –SUMO1) or 150 mg (MiaPaCa-
2–6His–Flag–Nedd8) of proteins were used to isolate modified substrates. For each dish of MiaPaCa-2 cells 
with different treatment conditions, 2 mL of buffer 1 (6 M guanidinium chloride, 0.1 M Na2HPO4/ NaH2PO4, 
pH 8.0 plus 0.5% Triton X-100;  Sigma-Aldrich, T8787) were added directly to the cell monolayer. Lysates were 
sonicated 3 times for 30 seconds with a 1-minute break between pulses, to reduce viscosity. Protein concen-
tration was measured in untreated and treated samples, and Ni2+-NTA agarose resin (QIAGEN, 30210) was 
added with a ratio of 2 μL of resin for 1 mg of proteins. Samples were rotated at room temperature for 2 hours 
an 30 minutes, and beads were then washed once with 1 mL of buffer 1 and twice with 1 mL of prechilled buf-
fer 2 (50 mM NaH2PO4, 150 mM NaCl, 1% Tween-20, 5% glycerol, pH 8.0) plus 10 mM imidazole. Purified 
proteins were eluted after 2 hours at 4°C in 600 μL of buffer 2 plus 250 mM imidazole. Eluted proteins were 
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then incubated with 50 μL of anti–Flag M2 agarose beads (MilliporeSigma, F3165) and rotated at 4°C for 2 
hours and 30 minutes. Beads were then washed twice with 500 μL of prechilled buffer 2. Purified proteins were 
eluted in 100 μL of buffer 2 containing 0.1 μg/μL of Flag peptide (MilliporeSigma, F3290) by rotating at 4°C 
for 1 hour and 30 minutes. Eluted proteins were collected and analyzed by MS.
One step Ni2+ purification. Like the 2-step procedure but without the Flag purification and with little mod-
ifications, 5 mL of  guanidinium lysis buffer and 50 μL of  Ni2+-NTA beads were used per 15 cm diameter 
dishes of  cell culture. After washing with 8 M Urea buffers (pH8 then pH6.3), the bound proteins were elut-
ed using 1× Laemmli buffer containing 200 mM imidazole for 5 minutes at 95°C. For cell lysate, a fraction 
of  the guanidinium lysate was precipitated using ethanol procedure and proteins dissolved in 1× Laemmli 
buffer for 5 minutes at 95°C.
MS analysis. Protein extracts were loaded on NuPAGE 4%−12% Bis-Tris acrylamide gels according to 
the manufacturer’s instructions (Invitrogen). Running was stopped as soon as proteins stacked in a single 
band. Protein-containing bands were stained with Imperial Blue (Pierce), cut from the gel, and digested with 
high-sequencing-grade trypsin (Promega) before MS analysis according to Shevchenko et al. (44). MS analy-
sis was carried out by LC-MS/MS using an LTQ-Velos-Orbitrap or a Q Exactive Plus Hybrid Quadrupole-Or-
bitrap (Thermo Fisher Scientific) coupled online with a nanoLC Ultimate3000RSLC chromatography system 
(Dionex). A total of  5 μL corresponding to one-fifth of  the whole sample were injected in triplicate on the 
system. After sample preconcentration and washing on a Dionex Acclaim PepMap 100 C18 column (2 cm 
× 100 μm i.d. 100 Å, 5 μm particle size), peptides were separated on a Dionex Acclaim PepMap RSLC C18 
column (15 cm × 75 μm i.d., 100 Å, 2 μm particle size) at a flow rate of  300 nL/min, a 2-step linear gradient 
(4%−20% acetonitrile/H2O; 0.1% formic acid for 90 minutes and 20%−45% acetonitrile/H2O; 0.1% formic 
acid for 30 minutes). For peptide ionization in the nanospray source, voltage was set at 1.9 kV, and the capil-
lary temperature was set at 275°C. All samples were measured in a data-dependent acquisition mode. Each 
experiment was preceded by a blank run to monitor system background. The peptide masses were measured 
in the LTQ-velos-orbitrap in a survey full scan (scan range 300−1700 m/z, with 30 K FWHM resolution at 
m/z = 400, target AGC value of  1 × 106, and maximum injection time of  200 ms). In parallel to the high-res-
olution full scan in the Orbitrap, the data-dependent collision-induced dissociation (CID) scans of  the 10 
most intense precursor ions were fragmented and measured in the linear ion trap (normalized collision energy 
of  35%, activation time of  10 ms, target AGC value of  1 × 104, maximum injection time 100 ms, and isola-
tion window 2 Da). Parent masses obtained in Orbitrap analyzer were automatically calibrated on 445.1200 
locked mass. Dynamic exclusion was implemented with a repeat count of  1 and exclusion time of  30 seconds.
In the Q Exactive Plus Hybrid Quadrupole-Orbitrap, the peptide masses were measured in a survey 
full scan (scan range 375–1500 m/z, with 70 K FWHM resolution at m/z = 400, target AGC value of  3 × 
106 and maximum injection time of  100 ms). Following the high-resolution full scan in the Orbitrap, the 
10 most intense data-dependent precursor ions were successively fragmented in higher-energy collisional 
dissociation (HCD) cell and measured in Orbitrap (normalized collision energy of  25%, activation time of  
10 ms, target AGC value of  1 × 103, intensity threshold 1 × 104 maximum injection time 100 ms, isolation 
window 2 m/z, 17.5 K FWHM resolution, scan range 200–2000 m/z). Dynamic exclusion was implement-
ed with a repeat count of  1 and exclusion time of  20 seconds.
MS data analysis. Raw files generated from MS analysis were processed using Proteome Discoverer 
1.4.1.14 (Thermo Fisher Scientific). This software was used to search data via in-house Mascot server 
(version 2.3.0; Matrix Science) against the Human database subset of  the SwissProt database (version 
2017.03, 20184 human entries). A database search was done by using the following settings: a maxi-
mum of  2 trypsin miscleavage allowed, methionine oxidation and protein N-acetylation as dynamic 
modifications, and cysteine carbamido-methylation as fixed modification. A peptide mass tolerance 
of  6 ppm and a fragment mass tolerance of  0.8 Da were allowed for search analysis. Only peptides 
identified with a FDR < 1% were used for protein identification.
Protein expression. NUPR1 was expressed and purified as described (12). A codon-optimized vector con-
taining residues 1–520 of importin-α3 was synthetically produced by Nzytech. The protein was expressed over-
night in BL21 E. coli strain at 37°C, in LB medium, after induction with 1 mM (final concentration) of IPTG 
(isopropylthio-galacto-pyranoside), when the culture had reached an absorbance at 600 nm between 0.6 and 
1.0. Purification was similar to that described for NUPR1 (12), except that the final polish purification step was 
carried out with a Superdex G200 16/60 in buffer Tris (50 mM, pH 8.0) with 200 mM NaCl, running on an 
AKTA FPLC (GE Healthcare) by following the absorbance at 280 nm.
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CD and fluorescence spectroscopies. The experimental set-up for CD and fluorescence spectroscopies was 
the same described previously (12). The temperature was 25°C for both techniques, and protein concen-
trations were 10 μM of  NUPR1 and 5 μM of  importin-α3 for the fluorescence experiments, and 20 μM of  
NUPR1 and 5 μM of  importin-α3 for the CD experiments.
ITC. The experimental set-up and data processing of  ITC experiments has been described previously 
(12). Importin-α3 (100–110 μM) was loaded into the syringe, and NUPR1 (5–10 μM) into the calorimetric 
cell in buffer Tris 50 mM, pH 8. Reverse titrations (NUPR1 in the syringe and importin-α3 in the calorimet-
ric cells) were also carried out, but direct and reverse titrations provided similar thermodynamic binding 
parameters. The temperature for all the experiments was 25°C. The binary experiments (interaction of  
NUPR1 with importin-α3) were analyzed applying a model considering a single binding site (1:1 stoichi-
ometry for the NUPR1/importin-α3 interaction). For experiments in the presence of  ZZW-115, a concen-
tration of  the compound of  100 μM was kept constant during the titration. These ternary experiments were 
analyzed in 2 ways: (a) considering an apparent quasibinary system with a single binding site displaying 
apparent thermodynamic binding parameters implicitly dependent on the concentration of  ZZW-115 and 
(b) considering an exact ternary system with a single binding site displaying intrinsic thermodynamic bind-
ing parameters explicitly dependent on the concentration of  ZZW-115 through cooperative interaction 
parameters (45, 46). The concentration of  ZZW-115 in the calorimetric cell was much higher than its disso-
ciation constant for its interaction with NUPR1, and the data analysis with both models gave similar values 
for the reduction in affinity for the NUPR1/importin-α3 interaction caused by the presence of  ZZW-115.
PLA. MiaPaCa-2 cells were seeded on coverslips and transfected with 2 μg of  plasmid DNA (Nupr1-Flag 
or importin-α3–Flag) using Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific). MiaPaCa-
2–6HF–SUMO1 cells, previously described (21), were used to measure the SUMOylation of  TP53. At the 
end of  the experiment, cells were washed in PBS, fixed, and permeabilized before immunostaining with 
Duolink In Situ (MilliporeSigma) following the manufacturer’s protocol. Anti-NUPR1 (rabbit, homemade), 
-p53 (rabbit, Santa Cruz Biotechnology, sc-6243), -MRE11 (rabbit, Novus Biologicals, NB100-142), or -Flag 
(mouse, MilliporeSigma, F1804) were used. Image acquisition was carried out on a Nikon Eclipse 90i fluo-
rescence microscope. ImageJ (NIH) was used to count the number of  red dots.
Use of  genotoxic agents. DNA breaks within different cancer cell lines (U87 and U251, glioblastoma 
cells; MiaPaCa-2, PDAC cell line; AOIPC, PDAC patient–derived cells; HT29, colon carcinoma; and 
the boosting effect of  ZZW-115) was evaluated by γH2AX immunofluorescence staining. Cells were 
treated with TMZ (180 μM), 5-FU (10 μM), Gemcitabine (15 μM), Oxaliplatin (12.5 μM), or γ-radiation 
(6 Gy) alone or in combination with ZZW-115 (1.5 μM), and DNA damages were quantified after 12 
hours. Human PDAC–associated fibroblasts were used as nontransformed cells. Sorafenib (0.5 μM) was 
used on HepG2 (hepatocarcinoma) cells as a negative control since it does not induce DNA damage.
Western blotting. Proteins were resolved by SDS-PAGE, and transferred to nitrocellulose membranes 
for 1 hour. Then, membranes were blocked 1 hour at room temperature with TBS (Tris buffered saline 
solution) and 5% BSA, and blotted overnight in TBS 5% BSA containing primary antibodies (1:500; 
anti-p53 [rabbit, Santa Cruz Biotechnology Inc., sc-6243], -MRE11 [rabbit, Novus Biologicals, NB100-
142], -LSD1 [mouse, Santa Cruz Biotechnology Inc., sc-271720]). After extensive washes in TBS 0.1% 
Tween-20, membranes were incubated 1 hour at room temperature with HRP-conjugated secondary 
antibodies at 1:5000 before being revealed with Enhanced chemo-luminescence (ECL). Acquisition was 
performed with a Fusion FX7 imager (Vilber-Lourmat).
Animals. Female CAnN.Cg-Foxn1nu/Crl BALB/c nude mice were provided by Charles River Laboratories. 
Mice were kept within the Experimental Animal House of the Centre de Cancérologie de Marseille, pôle Lumi-
ny (CRCM). Ten million MiaPaCa-2 cells or U87-red glioblastoma were inoculated s.c. in nude mice (6 weeks 
old), and they were separated into 4 groups of 5 or into 4 groups of 6 subjects each, respectively. Mice injected 
with MiaPaCa-2 cells were treated with 0.5% DMSO in physiologic serum (vehicle), 20 mg/kg 5-FU (5 days per 
week), 2.5 mg/kg of ZZW-115 (daily), and a combination of 20 mg/kg 5-FU with 2.5 mg/kg ZZW-115 when 
the tumor volume reached 300 mm3. Mice injected with U87-red glioblastoma were treated daily with 0.5% 
DMSO in physiologic serum (vehicle), 5 mg/kg of TMZ, 2.5 mg/kg of ZZW-115, and a combination of 5 mg/
kg TMZ with 2.5 mg/kg ZZW-115 when the tumor volume reached 300 mm3. Mice with MiaPaCa-2 xenografts 
were sacrificed after 30 days of treatment. Every 3 days, the mice were weighed and the tumor volumes were 
measured. Mice with U87 xenografts were sacrificed after 21 days of treatment, except 3 mice from the combi-
nation group. These 3 mice were kept for an additional 25-day period without any additional treatment.
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Immunofluorescence of  cultured cells. Cells were seeded in 12-well plates on coverslips and treated with ZZW-
115. After fixation, cells were incubated with the following antibodies at 1:100 dilution: rabbit anti-NUPR1 
primary antibody (homemade) or γH2AX primary antibody (ab26350, Abcam). After washing steps, samples 
were incubated in the presence of  secondary antibodies at 1:200 dilution (goat anti–mouse Alexa Fluor 488, 
A28175, or goat anti–rabbit Alexa Fluor 488, A27034, both from Thermo Fisher Scientific). DAPI (D1306, 
Thermo Fisher Scientific) was used to stain the nucleus. Image acquisition of  Alexa Fluor 488–derived fluo-
rescence and DAPI staining was performed using an LSM 880 controlled by Zeiss Zen Black. Colocalization 
analysis and measurement of  both channels was conducted by using the ImageJ Coloc 2 plugin.
Immunofluorescence staining of  tumor samples. Immunofluorescence staining was performed on 5 μm–thick 
paraffin-embedded tissue sections. The following antibodies were used: Ki67 (ab92742), γH2AX (ab26350) 
(both from Abcam), cleaved caspase-3 (9661; Cell Signaling Technology), and anti-NUPR1 (homemade). Pri-
mary antibodies were diluted 1:200 and secondary antibodies (goat anti-mouse IgG [H+L] Alexa Fluor 488 
[A28175] and goat anti-rabbit IgG [H+L] Alexa Fluor 488 [A27034], both from Thermo Fisher Scientific) were 
diluted 1:500. Signals were detected with an LSM 880 controlled by Zeiss Zen Black. Colocalization analysis 
and measurement of both channels was performed by ImageJ software.
In vitro (cell-free) SUMOylation assay. In vitro SUMO assay was performed using a SUMOylation kit by 
Enzo Life Sciences according to manufacturer’s protocol. Reactions containing SUMO1, SUMO2, and 
SUMO3; E1 or E2 (Ubc9); and RanGAP1 or p53 in the presence of  recombinant WT NUPR1 (2 μM), 
Thr68Gln (2 μM), and Ala33Gln/Thr68Gln (2 μM) NUPR1 mutants or in the presence of  NUPR1 with 
ZZW-115 (100 μM) were incubated 1 hour at 37°C. SUMOylation of  RanGAP1 or p53 were analyzed by 
Western blotting using rabbit anti-SUMO1 or SUMO2/3 antibodies provided by the kit (BML-UW8955; 
SUMO-1, rabbit polyclonal antibody, BML-PW8330; SUMO-2/3, rabbit polyclonal antibody, BML-
PW9465).
Statistics. Statistical analyses were performed by using the unpaired 2-tailed Student t test or 1-way ANOVA 
with Tukey’s post hoc test. Values are expressed as mean ± SEM. Data are representative of at least 3 inde-
pendent experiments with technical triplicates completed. A P value less than 0.05 was considered significant.
Study approval. All experimental protocols were carried out in accordance with the Guide for the Care and 
Use of  Laboratory Animals (National Academies Press, 2011). All experimental procedures on animals were 
approved by the Comité d’éthique de Marseille numéro 14 (C2EA-14).
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